Avinger, Inc. (AVGR) Stock Analysis

Avinger, Inc. (AVGR) Healthcare & Pipeline Overview

Avinger, Inc. specializes in image-guided, catheter-based systems for treating peripheral arterial disease (PAD). Their lumivascular platform, featuring real-time intravascular imaging, differentiates them in the medical device market. They cater to interventional cardiologists, vascular surgeons, and interventional radiologists in the United States and internationally.

What Is the Investment Thesis for AVGR?

Avinger, Inc. operates in the growing market for PAD treatment, offering a differentiated technology platform with its lumivascular imaging. Key value drivers include the adoption of its Pantheris and Ocelot catheters, as well as the potential success of its IMAGE-BTK product. The company's small size and negative profit margin of -239.4% present significant risks. Growth catalysts include expanding its sales network and securing favorable reimbursement policies. Investors should closely monitor Avinger's ability to increase revenue, manage costs, and achieve profitability in the competitive medical device landscape. The company's beta of 1.09 suggests a market-correlated risk profile.

Based on FMP financials and quantitative analysis

AVGR Key Highlights

Avinger's lumivascular platform integrates OCT imaging with interventional catheters for real-time visualization during PAD procedures.

• The company's product portfolio includes Ocelot catheters for penetrating total blockages and Pantheris for precise plaque removal.
• Avinger markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists.
• The company's gross margin stands at 26.2%.
• Avinger has a negative profit margin of -239.4%.

Who Are AVGR's Competitors?

AVGR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AVGR's Key Strengths?

Proprietary lumivascular platform with real-time imaging capabilities.

• Specialized product portfolio targeting PAD treatment.
• Focus on image-guided technology for enhanced precision.
• Established relationships with key opinion leaders in the field.

What Are AVGR's Weaknesses?

Limited financial resources and negative profit margin.

• Small market capitalization and potential liquidity concerns.
• Dependence on a limited number of products.
• Intense competition in the medical device industry.

What Could Drive AVGR Stock Higher?

Potential FDA approval and commercial launch of IMAGE-BTK for below-the-knee PAD lesions.

• Continued expansion of the sales network and increased adoption of Pantheris.
• Positive clinical trial results demonstrating the efficacy of Avinger's products.

What Are the Key Risks for AVGR?

Financial-distress signal — its Altman Z-Score of -48.15 sits in the distress zone (elevated bankruptcy risk).

• Competition from larger medical device companies with greater resources.
• Unfavorable reimbursement policies impacting the adoption of Avinger's products.
• Limited financial resources and the need to raise additional capital.
• Product liability claims and regulatory scrutiny.

What Are the Growth Opportunities for AVGR?

• Expansion of IMAGE-BTK Product Line: Avinger is developing IMAGE-BTK for below-the-knee PAD lesions. This represents a significant growth opportunity as BTK interventions are a critical area within PAD treatment. Successful development and commercialization of IMAGE-BTK could expand Avinger's addressable market and drive revenue growth. The market for BTK interventions is expected to grow as the prevalence of critical limb ischemia (CLI) increases.
• Geographic Expansion: Avinger currently operates in the United States and internationally. Expanding its geographic footprint into new markets, particularly in Europe and Asia, could significantly increase its revenue potential. These regions have growing aging populations and increasing awareness of PAD, creating a favorable environment for Avinger's products. Strategic partnerships and distribution agreements will be crucial for successful geographic expansion.
• Increased Adoption of Pantheris Atherectomy Device: Pantheris is Avinger's image-guided atherectomy device. Increasing its adoption among interventional cardiologists, vascular surgeons, and interventional radiologists is a key growth driver. This can be achieved through targeted marketing efforts, clinical studies demonstrating improved outcomes, and training programs for physicians. The atherectomy device market is growing, driven by the need for less invasive PAD treatment options.
• Strategic Partnerships and Acquisitions: Avinger could pursue strategic partnerships or acquisitions to expand its product portfolio, access new technologies, or enter new markets. Collaborating with other medical device companies or research institutions could accelerate innovation and drive growth. Acquisitions could provide Avinger with complementary products or access to new customer segments.
• Development of Next-Generation Lumivascular Technology: Avinger should continue to invest in research and development to enhance its lumivascular platform and develop next-generation technologies. This could include improving imaging resolution, developing new catheter designs, or expanding the applications of its technology to other vascular diseases. Innovation is crucial for maintaining a competitive edge in the medical device industry.

What Are AVGR's Competitive Advantages?

• Proprietary lumivascular platform integrating OCT visualization with interventional catheters.
• Image-guided technology providing real-time intravascular imaging during PAD procedures.
• Specialized product portfolio targeting specific PAD treatment needs.

What Does AVGR Do?

Avinger, Inc., established in 2007 and headquartered in Redwood City, California, is a medical device company dedicated to developing and commercializing innovative solutions for treating peripheral arterial disease (PAD). The company's core technology is its lumivascular platform, which combines optical coherence tomography (OCT) visualization with interventional catheters. This integration provides physicians with real-time intravascular imaging during PAD procedures, enhancing precision and improving patient outcomes. Avinger's product portfolio includes the Lightbox imaging consoles, the Ocelot family of catheters designed to penetrate total blockages in arteries, and Pantheris, an image-guided atherectomy device for precise removal of arterial plaque. Additionally, Avinger offers first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, utilizing a rotational spinning technique for navigating CTOs. The company is also developing IMAGE-BTK for treating PAD lesions below-the-knee. Avinger markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists in the United States and internationally, aiming to establish itself as a leader in the image-guided PAD treatment market.

What Products and Services Does AVGR Offer?

• Designs image-guided, catheter-based systems for treating peripheral arterial disease (PAD).
• Manufactures and sells the Lightbox imaging consoles.
• Develops and markets the Ocelot family of catheters for penetrating arterial blockages.
• Offers the Pantheris image-guided atherectomy device for removing arterial plaque.
• Provides Wildcat and Kittycat 2 CTO-crossing catheters.
• Developing IMAGE-BTK for treating PAD lesions below-the-knee.

How Does AVGR Make Money?

• Avinger generates revenue through the sale of its lumivascular products, including Lightbox imaging consoles and catheters.
• The company targets interventional cardiologists, vascular surgeons, and interventional radiologists.
• Avinger markets and sells its products in the United States and internationally.

What Industry Does AVGR Operate In?

Avinger operates within the medical device industry, specifically targeting the peripheral arterial disease (PAD) treatment market. This market is driven by the increasing prevalence of PAD due to aging populations and rising rates of diabetes and obesity. The competitive landscape includes larger medical device companies with established market presence, as well as smaller, specialized players. Avinger's lumivascular technology aims to differentiate it from competitors by providing real-time imaging during procedures, potentially leading to improved outcomes and market share gains.

Who Are AVGR's Key Customers?

• Interventional cardiologists
• Vascular surgeons
• Interventional radiologists

The most recent 10 insider filings for Avinger, Inc. break down as 5 sales and 5 purchases. On net that is roughly 142K shares acquired (about $159K) — insiders putting money in tends to read as conviction.

Wall Street analysts project Avinger, Inc. revenue of about $17.8M for fiscal 2026, with EPS near $-0.74.

Avinger, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -48.15 places it in the distress zone, a signal of elevated financial risk.

Avinger, Inc. (AVGR) Valuation Context

Valued at $1.52M, AVGR is classified as a micro-cap stock.

AVGR Revenue & Earnings Trend

In Q3 FY2024, AVGR generated $1.6M in top-line revenue, marking a sequential decrease of 10.7%. The company recorded a net loss of $3.7M, with diluted EPS of $-1.82. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely.

Company Profile

Avinger, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Nabeel P. Subainati CPA. AVGR has traded publicly since 2015.

AVGR Financials

AVGR Latest News

Common Questions About AVGR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources